https://www.daiichi-sankyo.eu/media/european-news/news-detail/ema-validates-and-grants-accelerated-assessment-for-trastuzumab-deruxtecan-for-the-treatment-of-her2-positive-metastatic-breast-cancer/ 2023-11-09T20:58:33+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-initiates-clinical-development-of-sixth-dxd-adc-ds-6000-with-sarah-cannon-research-institute/ 2021-02-02T16:28:25+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/herthena-lung01-phase-2-study-of-daiichi-sankyos-patritumab-deruxtecan-initiated-in-patients-with-egfr-mutated-nsclc/ 2021-02-02T16:39:14+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/trastuzumab-deruxtecan-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-a-prior-anti-her2-based-regimen/ 2022-08-18T15:09:25+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-appoints-ken-takeshita-md-as-global-head-of-rd/ 2021-02-22T13:14:52+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-approved-in-the-eu-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-one-or-more-prior-anti-her2-based-regimens/ 2022-08-18T15:16:38+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-and-lysa-lysarc-calym-enter-research-collaboration-for-valemetostat-in-patients-with-relapsed-refractory-b-cell-lymphoma/ 2021-02-24T08:52:39+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-significantly-delayed-disease-progression-in-destiny-breast02-phase-3-trial-versus-physicians-choice-of-treatment-in-patients-with-her2-positive-metastatic-breast-cancer/ 2022-08-18T15:27:02+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/destiny-lung02-phase-2-trial-of-enhertur-initiated-in-patients-with-her2-mutated-metastatic-non-small-cell-lung-cancer/ 2021-03-29T09:32:36+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/destiny-crc02-phase-2-trial-of-enhertur-initiated-in-patients-with-her2-overexpressing-advanced-colorectal-cancer/ 2021-04-06T09:43:21+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/phase-1-2-trial-initiated-for-daiichi-sankyos-menin-inhibitor-ds-1594-in-patients-with-acute-myeloid-leukemia-and-acute-lymphoblastic-leukemia/ 2021-04-07T09:27:33+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-initiates-phase-2-trial-to-evaluate-pexidartinib-in-japanese-patients-with-tgct/ 2021-04-09T09:03:00+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/real-world-edoxaban-vte-data-show-low-rates-of-bleeding-and-vte-events-reported-after-12-months-of-edoxaban-treatment/ 2023-11-09T14:58:41+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-continues-to-make-bold-strides-in-oncology-across-dxd-adc-portfolio-at-2022-esmo/ 2022-09-06T16:18:42+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/new-data-further-strengthens-important-role-of-lixianar-edoxaban-in-managing-complex-patient-populations-with-atrial-fibrillation-af/ 2022-09-06T16:40:26+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/latest-simulation-analyses-from-the-santorini-registry-indicates-that-adding-bempedoic-acid-in-the-lipid-lowering-treatment-algorithm-might-help-more-patients-achieve-ldl-c-recommended-goals/ 2022-09-06T16:43:43+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/datopotamab-deruxtecan-plus-durvalumab-showed-promising-clinical-activity-in-the-first-line-advanced-non-small-cell-lung-cancer-setting-in-tropion-lung04-phase-1b-trial/ 2023-09-14T09:48:35+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-opens-new-affiliate-for-oncology-in-greece/ 2024-07-15T09:32:07+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-trastuzumab-deruxtecan-now-available-via-the-cancer-drugs-fund-for-the-treatment-of-her2-positive-metastatic-breast-cancer/ 2021-04-20T08:41:52+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-demonstrated-strong-and-durable-tumor-responses-in-previously-treated-her2-mutant-advanced-lung-cancer-in-destiny-lung02-phase-2-trial/ 2023-09-14T09:55:03+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-and-astrazeneca-enter-new-global-development-and-commercialization-collaboration-for-daiichi-sankyos-adc-ds-1062/ 2020-08-03T09:16:13+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/multidisciplinary-think-tank-proposes-recommendations-to-improve-holistic-cardiovascular-care-in-europe/ 2024-08-06T16:38:29+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/new-two-years-follow-up-data-from-etna-af-europe-reaffirms-benefit-of-lixianar-edoxaban-in-people-with-atrial-fibrillation/ 2021-04-26T09:44:48+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-her2-mutant-advanced-non-small-cell-lung-cancer/ 2023-09-15T16:11:35+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/datrowayr-type-ii-variation-application-validated-in-the-eu-as-first-line-treatment-for-patients-with-metastatic-triple-negative-breast-cancer-who-are-not-candidates-for-immunotherapy/ 2026-01-08T18:09:17+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/etna-af-europe-registry-data-on-lixianar-edoxaban-published-in-a-leading-cardiology-journal-highlights-important-clinical-considerations-for-treating-elderly-patients-with-atrial-fibrillation/ 2023-11-09T20:59:05+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/new-subgroup-analyses-of-clear-outcomes-data-showed-bempedoic-acid-reduced-the-risk-of-major-adverse-cardiovascular-events-across-various-patient-groups/ 2024-08-06T16:38:16+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/quizartinib-recommended-for-approval-in-eu-by-chmp-for-patients-with-newly-diagnosed-flt3-itd-positive-aml/ 2023-09-15T16:13:51+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/first-in-class-cholesterol-lowering-treatment-nilemdor-and-its-combination-with-ezetimibe-nustendir-approved-in-europe-to-lower-ldl-cholesterol-and-reduce-cardiovascular-risk/ 2024-08-06T16:38:40+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/nilemdor-delivers-significant-cholesterol-lowering-in-addition-to-statin-therapy-which-is-maintained-during-25-years-of-treatment/ 2023-11-09T20:59:16+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-and-genesis-pharma-enter-exclusive-agreement-for-vanflytar-commercialization-in-central-and-eastern-europe/ 2026-01-08T18:23:36+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/new-12-month-analysis-data-from-etna-af-non-interventional-study-show-low-bleeding-and-ich-rates-in-frail-and-elderly-af-patients-on-lixiana-edoxaban-during-routine-clinical-care/ 2020-09-01T10:19:50+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-plus-pertuzumab-type-ii-variation-application-validated-in-the-eu-as-first-line-treatment-of-patients-with-her2-positive-metastatic-breast-cancer/ 2026-01-19T10:21:05+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-appoints-new-leadership-at-the-daiichi-sankyo-translational-research-center-europe/ 2026-01-22T08:47:57+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/datopotamab-deruxtecan-late-breaking-data-at-esmo-breast-shows-promising-preliminary-response-and-disease-control-in-patients-with-metastatic-triple-negative-breast-cancer/ 2021-05-07T09:29:00+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-approved-in-the-eu-as-the-first-her2-directed-therapy-for-patients-with-her2-mutant-advanced-non-small-cell-lung-cancer/ 2023-10-23T08:14:19+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-advances-science-across-three-lead-dxd-adcs-with-new-data-in-multiple-cancers-at-2021-asco-virtual-meeting/ 2021-06-04T10:39:54+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-type-ii-variation-application-validated-in-the-eu-as-post-neoadjuvant-treatment-for-patients-with-her2-positive-early-breast-cancer/ 2026-02-19T09:46:13+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-appoints-john-tsai-md-as-global-head-of-rd/ 2026-02-20T09:50:18+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/patritumab-deruxtecan-data-at-asco-demonstrates-tumor-response-across-multiple-resistance-mechanisms-in-patients-with-advanced-egfr-mutated-nsclc/ 2021-06-04T14:10:11+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/change-in-leadership-at-daiichi-sankyo-europe/ 2023-11-06T08:21:48+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/primary-endpoint-met-in-the-clear-outcomes-trial-of-bempedoic-acid-showing-statistically-significant-relative-risk-reduction-in-major-adverse-cv-events/ 2022-12-08T10:41:45+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/final-real-world-results-from-milos-german-cohort-demonstrate-strong-increase-in-ldl-c-goal-achievement-with-addition-of-bempedoic-acid/ 2024-11-25T15:22:25+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/valemetostat-data-at-eha-shows-promising-durable-tumor-response-in-patients-with-peripheral-t-cell-lymphoma-and-adult-t-cell-leukemia-lymphoma/ 2021-06-11T09:11:05+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/late-breaking-data-for-daiichi-sankyos-her3-directed-adc-patritumab-deruxtecan-in-egfr-mutated-nsclc-to-be-presented-at-2020-esmo-annual-meeting/ 2023-11-09T20:59:40+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-achieved-statistically-significant-overall-survival-reducing-the-risk-of-death-by-36-versus-trastuzumab-emtansine-t-dm1-in-patients-with-her2-positive-metastatic-breast-cancer-in-destiny-breast03/ 2022-12-08T13:03:04+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/delytactr-oncolytic-virus-g47-approved-in-japan-for-treatment-of-patients-with-malignant-glioma/ 2021-06-11T17:41:55+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-initiates-phase-2-study-of-patritumab-deruxtecan-in-patients-with-her3-expressing-advanced-colorectal-cancer/ 2020-09-15T15:08:35+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/datopotamab-deruxtecan-showed-encouraging-and-durable-efficacy-in-patients-with-heavily-pretreated-hr-positive-her2-low-or-negative-metastatic-breast-cancer/ 2022-12-09T10:53:06+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/destiny-breast09-head-to-head-first-line-phase-3-trial-of-enhertur-initiated-in-patients-with-her2-positive-metastatic-breast-cancer/ 2021-06-14T09:12:57+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/datopotamab-deruxtecan-showed-promising-responses-as-monotherapy-and-in-combination-with-durvalumab-in-patients-with-metastatic-triple-negative-breast-cancer-in-two-early-trials/ 2022-12-09T10:52:07+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/destiny-breast09-head-to-head-first-line-phase-3-trial-of-enhertur-initiated-in-patients-with-her2-positive-metastatic-breast-cancer-1/ 2021-06-14T09:18:08+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/delytactr-oncolytic-virus-g47-approved-in-japan-for-treatment-of-patients-with-malignant-glioma-1/ 2021-06-25T10:28:57+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/vanflytar-approved-in-the-eu-as-the-first-flt3-inhibitor-specifically-for-patients-with-newly-diagnosed-flt3-itd-positive-aml/ 2023-11-09T08:10:56+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-announces-late-breaking-phase-1-dose-expansion-data-for-patritumab-deruxtecan-in-patients-with-egfr-mutated-nsclc-at-esmo-2020/ 2023-11-09T21:01:17+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/destiny-gastric04-head-to-head-phase-3-trial-of-enhertur-initiated-in-patients-with-her2-positive-advanced-gastric-cancer/ 2021-07-08T09:52:59+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-significantly-improved-progression-free-survival-in-destiny-breast03-head-to-head-trial-versus-trastuzumab-emtansine-t-dm1-in-patients-with-her2-positive-metastatic-breast-cancer/ 2021-08-09T10:47:51+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-approved-in-japan-for-the-treatment-of-patients-with-her2-positive-metastatic-gastric-cancer/ 2023-11-09T21:01:36+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-advances-leadership-in-oncology-with-potentially-practice-changing-data-at-2021-esmo-congress/ 2021-09-07T10:01:35+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/destiny-gastric06-phase-2-trial-of-enhertur-initiated-in-china-in-patients-with-her2-positive-advanced-gastric-cancer/ 2021-09-16T13:19:50+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-approved-in-the-eu-for-patients-with-previously-treated-her2-positive-advanced-gastric-cancer/ 2022-12-19T14:33:43+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/datopotamab-deruxtecan-application-in-the-eu-for-patients-with-advanced-nonsquamous-non-small-cell-lung-cancer-voluntarily-withdrawn/ 2024-12-24T08:26:44+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/ds-7300-data-at-esmo-shows-promising-early-clinical-activity-in-patients-with-advanced-solid-cancers/ 2021-09-20T13:29:26+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-her2-low-metastatic-breast-cancer/ 2022-12-19T14:32:49+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/survey-reveals-88-of-western-europeans-would-like-better-information-on-breast-cancer-misconceptions-and-lack-of-awareness-of-the-disease-still-prevail/ 2026-03-17T08:18:04+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-demonstrated-clinically-meaningful-and-durable-response-in-patients-with-her2-positive-advanced-gastric-cancer-in-destiny-gastric02-phase-2-trial/ 2021-09-20T13:34:15+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-initiates-phase-1-trial-with-immuno-oncology-therapy-ds-1055-targeting-garp-on-activated-regulatory-t-cells/ 2023-11-09T21:01:48+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/datopotamab-deruxtecan-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-previously-treated-metastatic-hr-positive-her2-negative-breast-cancer/ 2025-01-31T15:16:20+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-granted-priority-review-in-the-us-for-treatment-of-her2-positive-metastatic-gastric-cancer/ 2023-11-09T21:02:11+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-type-ii-variation-application-validated-by-ema-for-the-treatment-of-her2-mutant-metastatic-non-small-cell-lung-cancer/ 2023-01-04T14:32:17+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/destiny-breast05-head-to-head-phase-3-trial-of-enhertur-versus-t-dm1-initiated-in-patients-with-her2-positive-early-breast-cancer-at-high-risk-after-neo-adjuvant-therapy/ 2023-11-09T21:02:38+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-creates-new-oncology-business-unit/ 2020-11-11T20:09:14+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-reduced-the-risk-of-disease-progression-or-death-by-72-versus-trastuzumab-emtansine-t-dm1-in-patients-with-her2-positive-metastatic-breast-cancer/ 2021-09-20T13:36:34+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/phase-2-destiny-gastric01-trial-of-ds-8201-versus-chemotherapy-met-primary-endpoint/ 2020-01-27T09:31:00+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/pooled-analyses-show-nilemdor-significantly-lowers-cholesterol-in-different-subgroups-in-phase-3-data-presented-at-aha-2020/ 2020-11-16T10:51:13+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-demonstrated-robust-and-durable-tumor-response-of-549-in-patients-with-her2-mutant-metastatic-non-small-cell-lung-cancer/ 2021-09-20T13:40:42+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-approved-in-the-eu-as-the-first-her2-directed-therapy-for-patients-with-her2-low-metastatic-breast-cancer/ 2023-01-31T12:28:25+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-recommended-for-approval-in-the-eu-by-chmp-for-patients-with-her2-low-or-her2-ultralow-metastatic-breast-cancer-following-at-least-one-endocrine-therapy/ 2025-03-06T15:57:51+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/datopotamab-deruxtecan-shows-encouraging-tumor-response-in-patients-with-advanced-non-small-cell-lung-cancer-with-actionable-genomic-alterations/ 2021-09-20T13:45:17+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-demonstrated-statistically-significant-and-clinically-meaningful-improvement-in-overall-survival-in-patients-with-her2-positive-metastatic-gastric-cancer-at-interim-analysis-of-destiny-gastric04-phase-3-trial/ 2025-04-04T08:37:19+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-to-present-new-data-for-her2-and-her3-directed-dxd-adcs-at-sabcs/ 2023-11-10T06:54:38+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-europe-highlights-need-to-address-the-perception-and-classification-of-cvd-risk-with-data-presentations-at-eas-2022/ 2022-05-24T17:09:00+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/esperion-and-daiichi-sankyo-europe-announce-125-million-amendment-to-their-collaboration-including-resolution-of-pending-litigation/ 2024-01-03T13:44:14+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/declaration-of-principle-supply-chain-due-diligence-act/ 2024-01-11T10:13:05+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-granted-breakthrough-therapy-designation-in-us-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-one-or-more-prior-anti-her2-based-regimens/ 2021-10-04T08:46:17+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/new-first-in-class-cholesterol-lowering-treatment-nilemdor-and-its-combination-with-ezetimibe-nustendir-approved-in-europe/ 2020-08-03T09:23:48+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/people-who-have-had-covid-19-more-likely-to-develop-cardiovascular-disease-new-report-highlights-the-need-to-refocus-on-cardiovascular-care/ 2022-05-24T17:15:36+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-granted-breakthrough-therapy-designation-in-the-us-for-her2-mutant-metastatic-non-small-cell-lung-cancer/ 2020-08-03T09:22:50+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-investiert-ca-eine-milliarde-euro-in-deutschland-standort-pfaffenhofen-bayern-wird-zu-internationalem-innovationszentrum-ausgebaut/ 2024-02-15T11:44:37+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/second-clinical-trial-collaboration-initiated-to-evaluate-datopotamab-deruxtecan-in-combination-with-keytrudar-pembrolizumab-in-patients-with-metastatic-non-small-cell-lung-cancer/ 2021-10-24T15:53:34+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-approved-in-the-eu-as-first-her2-directed-therapy-for-patients-with-hr-positive-her2-low-or-her2-ultralow-metastatic-breast-cancer-following-at-least-one-endocrine-therapy/ 2025-04-04T08:38:33+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-granted-breakthrough-therapy-designation-in-the-us-for-her2-positive-metastatic-gastric-cancer/ 2023-11-10T06:54:49+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/patritumab-deruxtecan-continues-to-show-promising-clinical-activity-in-patients-across-subtypes-of-metastatic-breast-or-lung-cancer/ 2022-06-03T15:23:19+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-to-present-new-research-data-across-dxd-adc-portfolio-at-2020-asco-annual-meeting/ 2020-07-24T10:39:26+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/trastuzumab-deruxtecan-type-ii-variation-application-validated-by-ema-for-the-treatment-of-her2-positive-advanced-gastric-cancer/ 2021-11-02T18:39:15+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/datrowayr-approved-in-the-eu-for-patients-with-previously-treated-metastatic-hr-positive-her2-negative-breast-cancer/ 2025-04-08T08:00:44+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-initiates-clinical-trial-with-5th-dxd-adc-ds-6157-in-collaboration-with-sarah-cannon-research-institute/ 2020-07-24T10:37:21+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-reduced-the-risk-of-disease-progression-or-death-by-50-vs-chemotherapy-in-patients-with-her2-low-metastatic-breast-cancer-with-hr-positive-and-hr-negative-disease/ 2022-06-07T17:41:49+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/tropion-breast01-phase-3-trial-of-datopotamab-deruxtecan-initiated-in-patients-with-hormone-receptor-positive-her2-negative-metastatic-breast-cancer/ 2021-11-18T11:23:39+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/ds-6000-suggests-early-clinical-activity-in-patients-with-advanced-ovarian-cancer-or-renal-cell-carcinoma/ 2022-06-07T17:50:00+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-europes-statement-re-esperion-therapeutics/ 2023-05-08T11:25:47+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/quizartinib-added-to-chemotherapy-demonstrates-superior-overall-survival-compared-to-chemotherapy-alone-in-adult-patients-with-newly-diagnosed-flt3-itd-positive-aml/ 2021-11-21T16:27:52+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/destiny-breast11-neoadjuvant-phase-3-trial-of-enhertur-initiated-in-patients-with-high-risk-her2-positive-early-stage-breast-cancer/ 2021-11-30T12:57:07+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-to-present-new-breast-cancer-data-across-dxd-adc-portfolio-at-2021-sabcs/ 2021-11-30T20:50:31+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/trastuzumab-deruxtecan-type-ii-variation-application-validated-by-ema-for-patients-with-her2-low-metastatic-breast-cancer-with-hr-positive-and-hr-negative-disease/ 2022-06-23T16:27:20+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/datopotamab-deruxtecan-continues-to-show-promising-durable-response-and-disease-control-in-patients-with-metastatic-triple-negative-breast-cancer/ 2021-12-07T11:55:07+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-granted-orphan-drug-designation-in-the-us-for-gastric-cancer/ 2023-11-09T20:57:08+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-additional-analyses-further-reinforce-groundbreaking-efficacy-in-patients-with-her2-positive-metastatic-breast-cancer/ 2021-12-09T09:38:01+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-significantly-improved-tumor-response-rate-and-overall-survival-in-her2-positive-metastatic-gastric-cancer-in-pivotal-phase-2-destiny-gastric01-trial/ 2023-11-09T20:56:52+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-continues-to-demonstrate-durable-responses-with-new-data-from-destiny-breast01-in-her2-positive-metastatic-breast-cancer/ 2023-11-10T06:54:59+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-showcases-latest-research-towards-creating-new-standards-of-care-for-patients-with-cancer-with-data-at-asco-and-eha/ 2023-06-05T14:44:25+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/results-from-first-combination-trial-of-enhertur-and-immune-checkpoint-inhibitor-in-patients-with-her2-expressing-metastatic-breast-cancer-presented-at-the-2020-san-antonio-breast-cancer-symposium/ 2023-11-10T06:53:58+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/valemetostat-pivotal-data-shows-promising-response-rates-in-patients-with-adult-t-cell-leukemia-lymphoma/ 2021-12-13T15:00:35+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-achieved-a-tumor-response-rate-of-453-in-patients-with-her2-positive-metastatic-colorectal-cancer-in-phase-2-destiny-crc01-trial/ 2023-11-09T20:56:43+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-demonstrated-clinically-meaningful-and-durable-responses-in-patients-across-multiple-her2-expressing-advanced-solid-tumors/ 2023-06-08T21:19:11+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/trastuzumab-deruxtecan-recommended-for-approval-in-the-eu-by-chmp-for-her2-positive-metastatic-breast-cancer/ 2020-12-14T14:49:29+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/datopotamab-deruxtecan-combinations-showed-encouraging-tumor-responses-in-patients-with-advanced-non-small-cell-lung-cancer-in-tropion-lung02-phase-1b-trial/ 2023-06-05T14:38:53+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/two-datopotamab-deruxtecan-applications-validated-in-the-eu-for-patients-with-advanced-nonsquamous-non-small-cell-lung-cancer-or-hr-positive-her2-negative-breast-cancer/ 2024-03-25T10:05:10+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/destiny-lung04-phase-3-trial-of-enhertur-initiated-in-patients-with-previously-untreated-her2-mutant-metastatic-non-small-cell-lung-cancer/ 2021-12-23T09:48:17+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-demonstrated-meaningful-clinical-activity-in-patients-with-her2-mutant-non-small-cell-lung-cancer-in-interim-analysis-of-phase-2-destiny-lung01-trial/ 2023-11-09T20:56:34+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/tropion-lung01-head-to-head-phase-3-trial-initiated-to-evaluate-datopotamab-deruxtecan-versus-docetaxel-in-previously-treated-patients-with-advanced-or-metastatic-nsclc-without-actionable-genomic-alterations/ 2020-12-14T15:36:13+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/patritumab-deruxtecan-granted-us-fda-breakthrough-therapy-designation-in-patients-with-metastatic-egfr-mutated-non-small-cell-lung-cancer/ 2021-12-23T09:49:55+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/tropion-lung05-phase-2-trial-of-datopotamab-deruxtecan-initiated-in-patients-with-advanced-or-metastatic-nsclc-with-actionable-genomic-alterations/ 2020-12-14T15:35:37+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/first-in-class-cholesterol-lowering-treatment-nilemdor-bempedoic-acid-tablet-and-its-combination-with-ezetimibe-nustendir-bempedoic-acid-and-ezetimibe-tablet-approved-in-switzerland/ 2021-02-02T11:33:17+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyo-announces-clinical-research-collaboration-to-evaluate-ds-1062-in-combination-with-keytrudar-pembrolizumab-in-metastatic-non-small-cell-lung-cancer/ 2023-11-09T20:56:21+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-type-ii-variation-application-validated-in-the-eu-for-previously-treated-patients-with-her2-positive-metastatic-solid-tumors/ 2025-09-11T14:39:48+02:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/chmp-issues-positive-opinions-for-both-bempedoic-acid-and-the-bempedoic-acid-ezetimibe-fixed-dose-combination-tablet-as-treatments-for-hypercholesterolaemia-and-significantly-reducing-cardiovascular-events/ 2024-03-25T09:37:57+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/trastuzumab-deruxtecan-type-ii-variation-application-validated-by-ema-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-a-prior-anti-her2-based-regimen/ 2021-12-28T09:57:56+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-granted-priority-review-in-the-us-for-patients-with-her2-positive-metastatic-breast-cancer-treated-with-a-prior-anti-her2-based-regimen/ 2022-01-17T12:35:39+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/new-research-data-across-dxd-adc-portfolio-at-wclc-showcases-daiichi-sankyos-continued-commitment-in-lung-cancer/ 2021-02-02T11:33:08+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/daiichi-sankyos-santorini-study-gets-underway-investigating-cholesterol-care-across-europe/ 2023-11-09T20:56:10+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-approved-in-the-eu-for-the-treatment-of-her2-positive-metastatic-breast-cancer/ 2021-02-02T11:33:01+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-receives-prime-ministers-award-from-the-japan-techno-economics-society/ 2021-02-02T11:32:52+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/enhertur-significantly-improved-both-progression-free-and-overall-survival-in-destiny-breast04-trial-in-patients-with-her2-low-metastatic-breast-cancer/ 2022-02-21T12:51:35+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/datopotamab-deruxtecan-and-enhertu-show-promising-early-clinical-activity-in-patients-with-advanced-non-small-cell-lung-cancer/ 2021-02-02T11:32:38+01:00 0.5 https://www.daiichi-sankyo.eu/media/european-news/news-detail/new-biomarker-analyses-from-patritumab-deruxtecan-phase-1-study-in-patients-with-egfr-mutated-nsclc-presented-at-wclc-2020/ 2021-02-02T11:10:14+01:00 0.5